Influenza vaccination in HIV-infected individuals: Systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety

Vaccine

Volumn 32, Issue 43, 2014, Pages 5585-5592

  Remschmidt, Cornelius ^a   Wichmann, Ole ^a   Harder, Thomas ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Efficacy and effectiveness; Evidence quality; HIV; Influenza; Systematic review; Vaccine

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE;

ADULT DISEASE; ARTHRALGIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILDHOOD DISEASE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE CONTUSION; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; META ANALYSIS; META ANALYSIS (TOPIC); MYALGIA; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; RIGOR; SEASONAL INFLUENZA; SKIN REDNESS; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); ADULT; AGED; IMMUNOLOGY; INFANT; INFLUENZA, HUMAN; MIDDLE AGED; OBSERVATIONAL STUDY; PRESCHOOL CHILD; STATISTICAL BIAS; YOUNG ADULT;

ADULT; AGED; BIAS (EPIDEMIOLOGY); CHILD, PRESCHOOL; HIV INFECTIONS; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84908511714     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.101     Document Type: Article

References (42)

1. Couch R.B. Influenza, influenza virus vaccine, and human immunodeficiency virus infection. Clin Infect Dis 1999, 28:548-551.
2. Safrin S., Rush J.D., Mills J. Influenza in patients with human immunodeficiency virus infection. Chest 1990, 98:33-37.
3. Radwan H.M., Cheeseman S.H., Lai K.K., Ellison I.R. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis 2000, 31:604-606.
4. Lin J.C., Nichol K.L. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001, 161:441-446.
5. Neuzil K.M., Reed G.W., Mitchel E.F., Griffin M.R. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999, 281:901-907.
6. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9:493-504.
7. Miotti P.G., Nelson K.E., Dallabetta G.A., Farzadegan H., Margolick J., Clements M.L. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989, 262:779-783.
8. Chadwick E.G., Chang G., Decker M.D., Yogev R., Dimichele D., Edwards K.M. Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994, 13:206-211.
9. Staprans S.I., Hamilton B.L., Follansbee S.E., Elbeik T., Barbosa P., Grant R.M., et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995, 182:1727-1737.
10. Kroon F.P., van Dissel J.T., de Jong J.C., Zwinderman K., van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000, 18:3040-3049.
11. Fine A.D., Bridges C.B., De Guzman A.M., Glover L., Zeller B., Wong S.J., et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 2001, 32:1784-1791.
12. Vigano A., Zuccotti G.V., Pacei M., Erba P., Castelletti E., Giacomet V., et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 48:289-296.
13. Cagigi A., Nilsson A., Pensieroso S., Chiodi F. Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. Lancet Infect Dis 2010, 10:499-503.
14. Remschmidt C., Wichmann O., Harder T. Methodological quality of systematic reviews on influenza vaccination. Vaccine 2014, 32:1678-1684.
15. Atashili J., Kalilani L., Adimora A.A. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis 2006, 6:138.
16. Anema A., Mills E., Montaner J., Brownstein J.S., Cooper C. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med 2008, 9:57-61.
17. Guyatt G.H., Oxman A.D., Schunemann H.J. GRADE guidelines-an introduction to the 10th-13th articles in the series. J Clin Epidemiol 2013, 66:121-123.
18. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924-926.
19. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. W64.
20. Shea B.J., Grimshaw J.M., Wells G.A., Boers M., Andersson N., Hamel C., et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007, 7:10.
21. Higgins J., Green S. Cochrane handbook of systematic reviews of interventions 2011, Cochrane Collaboration.
22. Ranieri R., Veronelli A., Santambrogio C., Pontiroli A.E. Impact of influenza vaccine on response to vaccination with pneumococcal vaccine in HIV patients. AIDS Res Hum Retroviruses 2005, 21:407-409.
23. Guyatt G.H., Thorlund K., Oxman A.D., Walter S.D., Patrick D., Furukawa T.A., et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol 2013, 66:173-183.
24. Madhi S.A., Dittmer S., Kuwanda L., Venter M., Cassim H., Lazarus E., et al. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. AIDS 2013, 27:369-379.
25. Madhi S.A., Maskew M., Koen A., Kuwanda L., Besselaar T.G., Naidoo D., et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011, 52:128-137.
26. Tasker S.A., Treanor J.J., Paxton W.B., Wallace M.R. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 131:430-433.
27. Yamanaka H., Teruya K., Tanaka M., Kikuchi Y., Takahashi T., Kimura S., et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39:167-173.
28. Huang K.L., Ruben F.L., Rinaldo C.R., Kingsley L., Lyter D.W., Ho M. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. JAMA 1987, 257:2047-2050.
29. Terragna A., Dodi F., Angelo M., Del Bono V., Admission E., Venerate R. The Walter Reed staging classification in the follow-up of HIV infection. N Engl J Med 1986, 315:1355-1356.
30. Jefferson T., Rivets A., Di Pietrantonj C., Demicheli V., Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2012, 8:CD004879.
31. Langley J.M., Vanderkooi O.G., Garfield H.A., Hebert J., Chandrasekaran V., Jain V.K., et al. Immunogenicity and safety of 2 dose levels of a thimerosal-free trivalent seasonal influenza vaccine in children aged 6-35 months: a randomized, controlled trial. J Pediatr Infect Dis Soc 2012, 1:55-63.
32. Khanlou H., Sanchez S., Babaie M., Chien C., Hamwi G., Ricaurte J.C., et al. The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunodeficiency virus-positive patients. Arch Intern Med 2006, 166:1417.
33. Zuccotti G.V., Cucchi C., Sala D., Giovannini M. Immunogenicity and safety of a virosomal influenza vaccine in HIV-infected children. Acta Paediatr 2002, 91:486. author reply 7.
34. Feola D.J., Garvy B.A., Rapp R.P., Thornton A.C. Blunted humoral response to influenza vaccination in patients exposed to zidovudine plus trimethoprim-sulfamethoxazole. Pharmacotherapy 2007, 27:937-947.
35. Kissling E., Valenciano M., Falcao J., Larrauri A., Widgren K., Pitigoi D., et al. "I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9. Euro Surveill 2009, 14.
36. Jefferson T. Influenza vaccination: policy versus evidence. BMJ 2006, 333:912-915.
37. Belongia E.A., Kieke B.A., Donahue J.G., Greenlee R.T., Balish A., Foust A., et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009, 199:159-167.
38. Beyer W.E. Heterogeneity of case definitions used in vaccine effectiveness studies - and its impact on meta-analysis. Vaccine 2006, 24:6602-6604.
39. Navarro-Mari J.M., Perez-Ruiz M., Cantudo-Munoz P., Petit-Gancedo C., Jimenez-Valera M., Rosa-Fraile M., et al. Influenza-like illness criteria were poorly related to laboratory-confirmed influenza in a sentinel surveillance study. J Clin Epidemiol 2005, 58:275-279.
40. Woolpert T., Brodine S., Lemus H., Waalen J., Blair P., Faix D. Determination of clinical and demographic predictors of laboratory-confirmed influenza with subtype analysis. BMC Infect Dis 2012, 12:129.
41. Kasper M.R., Wierzba T.F., Sovann L., Blair P.J., Putnam S.D. Evaluation of an influenza-like illness case definition in the diagnosis of influenza among patients with acute febrile illness in Cambodia. BMC Infect Dis 2010, 10:320.
42. Nelson J.C., Jackson M.L., Weiss N.S., Jackson L.A. New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among seniors. J Clin Epidemiol 2009, 62:687-694.